NCT06689566Recruiting
Evaluating Metabolic and Anti-inflammatory Effect of Genistein on Post-myocardial Infarction Patients
Source: ClinicalTrials.gov · Last updated 7 Aug 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The goal of this clinical trial is to learn if genistein works to provide a beneficial effect to show lipid lowering effect and anti-inflammatory effects and slow the progression of atherosclerosis in post-myocardial infarction adults. It will also learn about the safety of genistein. The main questions it aims to answer are: Does genistein lower triglyceride in participants? What medical problems do participants have when taking genistein? Researchers will compare the baseline, under treatment and washout period triglyceride, hsCRP to see if genistein works to decrease inflammation. Participants will: Take genistein every day for 3 months with a fixed dose manner. Afterwards, there will be 3 months washout period. Visit the clinic once every month for checkups and tests. Keep a diary of their symptoms.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 73 (estimated)
- First submitted
- 4 Nov 2024
- Start date
- Sept 2025
- Primary completion date
- Dec 2026
- Lead sponsor
- National Taiwan University Hospital
- Diseases
- Coronary artery disease
- NCT number
- NCT06689566
What you commit to
- Study type: Interventional
- Planned participants: 73
- From Sept 2025 to the primary completion date, Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients with prior history of carotid angioplasty, stenting, or carotid atherectomy
Other illness
- Major non-cardiac surgical or endoscopic procedure within past 6 months
- Symptomatic patients with Class IV heart failure (HF) (New York Heart Association \[NYHA\].
- Uncontrolled hypertension
- Uncontrolled diabetes
- History or evidence of active tuberculosis (TB) infection
- Active cancer under treatment
Other
- Pregnant or nursing (lactating) women
- Women of child-bearing potential
- Planned coronary revascularization (PCI or CABG)
- BMI \> 40 kg/m2
Who the study is looking for
- Written informed consent.
- Age ≥ 18 years.
- History of spontaneous myocardial infarction at least 28 days before recruitment.
- hsCRP ≥ 0.1 mg/dL
- BMI ≥ 27
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| National Taiwan University Hospital Coordinator of this site? Confirm its status | Taipei | Taiwan | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.